Weiqiang Qiao

Weiqiang Qiao

Auto-generated profile, based on publicly available information

Weiqiang Qiao

Department of Breast Surgery, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Neuroscience Letters
Verified
Journal Article
Closed access
ZJZhi-Qiang Jia
Zhi-Qiang Jia
SLSan-Qiang Li
San-Qiang Li
WQWei-Qiang Qiao
Wei-Qiang Qiao
WXWenzhong Xu
Wenzhong Xu
JXJian-Wu Xing
Jian-Wu Xing
XHXi-Jing He
Xi-Jing He

1 July 2019 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
WQWeiqiang Qiao
Weiqiang Qiao
HLHeyang Liu
Heyang Liu
WGWanying Guo
Wanying Guo
PLPeng Li
Peng Li
MDMiao Deng
Miao Deng

9 October 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WQWeiqiang Qiao
Weiqiang Qiao
ZJZhiqiang Jia
Zhiqiang Jia
HLHeyang Liu
Heyang Liu
QLQipeng Liu
Qipeng Liu
TZTing Zhang
Ting Zhang
SLSanqiang Li
Sanqiang Li
Despite initial indications that the transcription factor Twist could be used as a breast cancer prognostic marker, there still exists some controversy about its reliability. Thus, the aim of the present study was to assess the relationship between Twist expression and prognosis in breast carcinoma. We identified eligible studies that reported an association between Twist expression and breast cancer prognosis by searching the literature in PubMed, Embase, the Cochrane Library, and Web of Science databases, through June 5, 2017. Studies investigating Twist protein or mRNA expression as well as reporting survival data in breast cancer were included. The pooled hazard ratio (HR) and odds radio (OR) with a 95% confidence interval (95% CI) were used to estimate associations. A total of 2,671 patients from seven included studies were assessed, and the data indicated that increased Twist expression significantly correlated with poor overall survival (OS) (HR, 1.15; 95% CI, 1.00–1.33; P = 0.04) in breast cancer. In addition, we also observed a significant correlation of elevated Twist expression with larger tumor size (OR, 1.92; 95% CI, 1.31–2.81; P = 0.0009), lymph node involvement (OR, 3.81; 95% CI, 1.16–12.54; P = 0.03), higher nuclear grade (OR, 1.45; 95% CI, 1.06–2.00; P = 0.02), and positive human epidermal growth factor receptor 2 (HER2) status (OR, 1.49; 95% CI, 1.06–2.09; P = 0.02). However, no correlation between Twist expression and disease-free survival (DFS), age, estrogen receptor (ER) status, and progesterone receptor (PR) status was observed. Our results demonstrate that Twist over-expression is a statistically significant indicator of OS in breast cancer. In addition, our meta-analysis shows that increased Twist expression is significantly associated with larger tumor size, lymph node involvement, higher nuclear grade, and positive HER2 status.

1 August 2018 in Clinica Chimica Acta
Verified
Journal Article
Closed access
WQWeiqiang Qiao
Weiqiang Qiao
HLHeyang Liu
Heyang Liu
RLRuidong Liu
Ruidong Liu
QLQipeng Liu
Qipeng Liu
TZTing Zhang
Ting Zhang
MDMiao Deng
Miao Deng

1 September 2018 in Clinica Chimica Acta
Verified
Journal Article
Closed access
HLHeyang Liu
Heyang Liu
ZLZhuanzhen Li
Zhuanzhen Li
MDMiao Deng
Miao Deng
QLQipeng Liu
Qipeng Liu
TZTing Zhang
Ting Zhang
WQWeiqiang Qiao
Weiqiang Qiao

17 February 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WQWeiqiang Qiao
Weiqiang Qiao
LPLinlin Pan
Linlin Pan
CKChanggui Kou
Changgui Kou
KLKe Li
Ke Li
MYMing Yang
Ming Yang
Previous studies have shown that the poly (adenosine diphosphate-ribose) polymerase (PARP) level is a promising indicator of breast cancer. However, its prognostic value remains controversial. The present meta-analysis evaluated the prognostic value of PARP expression in breast cancer. Eligible studies were retrieved from the PubMed, Web of Science, Embase, and Cochrane Library databases through July 20, 2016. Studies investigating PARP expression as well as reporting survival data in breast cancer were included. Two independent reviewers carried out all literature searches. The pooled relative risk (RR) and hazard ratio (HR) with 95% confidence interval (95% CI) were applied to assess the association between PARP expression and the clinicopathological features and survival outcome in breast cancer. A total of 3506 patients from eight eligible studies were included. We found that higher PARP expression indicated a worse clinical outcome in early stage breast cancer, with a HR of 3.08 (95% CI, 1.14–8.29, P = 0.03) for disease-free survival and a HR of 1.82 (95% CI, 1.20–2.76; P = 0.005) for overall survival. Moreover, increased PARP expression was significantly associated with higher nuclear grade (RR, 1.51; 95% CI, 1.12–2.04; P = 0.008) in breast cancer. A similar correlation was detected in triple-negative breast cancer (TNBC; RR, 1.81; 95% CI, 1.04–3.17; P = 0.04). Our findings indicated that elevated PARP expression correlated with worse prognosis in early stage breast cancer. Furthermore, high PARP expression was associated with higher nuclear grade and TNBC.